Home > Research > Publications & Outputs > Living with age-related macular degeneration tr...

Research

Associated organisational unit

Links

Text available via DOI:

Keywords

View graph of relations

Living with age-related macular degeneration treatment: Patient experiences of being treated with ranibizumab (Lucentis) intravitreal injections

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Living with age-related macular degeneration treatment: Patient experiences of being treated with ranibizumab (Lucentis) intravitreal injections. / Thetford, Clare; Hodge, Suzanne; Harding, Simon et al.
In: British Journal of Visual Impairment, Vol. 31, No. 2, 05.2013, p. 89-101.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Thetford, C, Hodge, S, Harding, S, Taylor, S & Knox, P 2013, 'Living with age-related macular degeneration treatment: Patient experiences of being treated with ranibizumab (Lucentis) intravitreal injections', British Journal of Visual Impairment, vol. 31, no. 2, pp. 89-101. https://doi.org/10.1177/0264619613481778

APA

Thetford, C., Hodge, S., Harding, S., Taylor, S., & Knox, P. (2013). Living with age-related macular degeneration treatment: Patient experiences of being treated with ranibizumab (Lucentis) intravitreal injections. British Journal of Visual Impairment, 31(2), 89-101. https://doi.org/10.1177/0264619613481778

Vancouver

Thetford C, Hodge S, Harding S, Taylor S, Knox P. Living with age-related macular degeneration treatment: Patient experiences of being treated with ranibizumab (Lucentis) intravitreal injections. British Journal of Visual Impairment. 2013 May;31(2):89-101. doi: 10.1177/0264619613481778

Author

Thetford, Clare ; Hodge, Suzanne ; Harding, Simon et al. / Living with age-related macular degeneration treatment : Patient experiences of being treated with ranibizumab (Lucentis) intravitreal injections. In: British Journal of Visual Impairment. 2013 ; Vol. 31, No. 2. pp. 89-101.

Bibtex

@article{cdff70aa9e414fc9bd3e70961bd6755f,
title = "Living with age-related macular degeneration treatment: Patient experiences of being treated with ranibizumab (Lucentis) intravitreal injections",
abstract = "This study reports the results of a qualitative study of patient experiences of receiving treatment for wet age-related macular degeneration with ranibizumab (Lucentis)(R). Treatment involved monthly hospital visits for assessment and, where required, an intravitreal Lucentis injection. Qualitative narrative interviews were conducted with 22 patients, 18 of whom received treatment and were interviewed at two points during their treatment journey. Interviews allowed participants to reflect on their experiences of being assessed for and receiving this treatment. Overall, treated participants reported that while they had been apprehensive about treatment, the actual experience of it was far less unpleasant than they had expected. However, the data also revealed a number of issues surrounding the provision of information about treatment, as well as service delivery issues, which had considerable impact upon their experience.",
keywords = "Age-related macular degeneration , intravitreal injection , Lucentis , patient experience , ranibizumab , service delivery , wet age-related macular degeneration",
author = "Clare Thetford and Suzanne Hodge and Simon Harding and Sandra Taylor and Paul Knox",
year = "2013",
month = may,
doi = "10.1177/0264619613481778",
language = "English",
volume = "31",
pages = "89--101",
journal = "British Journal of Visual Impairment",
issn = "0264-6196",
publisher = "Association for the Education and Welfare of the Visually Handicapped",
number = "2",

}

RIS

TY - JOUR

T1 - Living with age-related macular degeneration treatment

T2 - Patient experiences of being treated with ranibizumab (Lucentis) intravitreal injections

AU - Thetford, Clare

AU - Hodge, Suzanne

AU - Harding, Simon

AU - Taylor, Sandra

AU - Knox, Paul

PY - 2013/5

Y1 - 2013/5

N2 - This study reports the results of a qualitative study of patient experiences of receiving treatment for wet age-related macular degeneration with ranibizumab (Lucentis)(R). Treatment involved monthly hospital visits for assessment and, where required, an intravitreal Lucentis injection. Qualitative narrative interviews were conducted with 22 patients, 18 of whom received treatment and were interviewed at two points during their treatment journey. Interviews allowed participants to reflect on their experiences of being assessed for and receiving this treatment. Overall, treated participants reported that while they had been apprehensive about treatment, the actual experience of it was far less unpleasant than they had expected. However, the data also revealed a number of issues surrounding the provision of information about treatment, as well as service delivery issues, which had considerable impact upon their experience.

AB - This study reports the results of a qualitative study of patient experiences of receiving treatment for wet age-related macular degeneration with ranibizumab (Lucentis)(R). Treatment involved monthly hospital visits for assessment and, where required, an intravitreal Lucentis injection. Qualitative narrative interviews were conducted with 22 patients, 18 of whom received treatment and were interviewed at two points during their treatment journey. Interviews allowed participants to reflect on their experiences of being assessed for and receiving this treatment. Overall, treated participants reported that while they had been apprehensive about treatment, the actual experience of it was far less unpleasant than they had expected. However, the data also revealed a number of issues surrounding the provision of information about treatment, as well as service delivery issues, which had considerable impact upon their experience.

KW - Age-related macular degeneration

KW - intravitreal injection

KW - Lucentis

KW - patient experience

KW - ranibizumab

KW - service delivery

KW - wet age-related macular degeneration

U2 - 10.1177/0264619613481778

DO - 10.1177/0264619613481778

M3 - Journal article

VL - 31

SP - 89

EP - 101

JO - British Journal of Visual Impairment

JF - British Journal of Visual Impairment

SN - 0264-6196

IS - 2

ER -